

Fiscal Year 2010 (FY10) Neurofibromatosis Research Program (NFRP) Reference Table of Award Mechanisms and Submission Requirements

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Clinical Trial Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: W81XWH-10-NFRP-CTA</p>	<p>All levels of experience.</p>	<ul style="list-style-type: none"> • Fund Phase 0, I, or II clinical trials relevant to neurofibromatosis (NF) and/or Schwannomatosis. Combinations of phases are permitted. • Preclinical data required. • Phase I or pilot clinical trial data required for Phase II clinical trial proposals. 	<ul style="list-style-type: none"> • The maximum period of performance is 4 years. • The maximum allowable funding for the entire period of performance is \$900,000 in direct costs. • Indirect costs may be proposed in accordance with your institution's negotiated rate agreement. 	<p>Pre-application (LOI*): April 29, 2010 5:00 p.m. Eastern time (ET)</p> <p>Application: May 20, 2010 11:59 p.m. ET</p>
<p>Investigator-Initiated Research Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: W81XWH-10-NFRP-IIRA</p>	<p>Principal Investigator: Must be an independent investigator <i>at or above</i> the level of Assistant Professor (or equivalent).</p> <p>Optional Qualified Collaborator: Must be <i>at or above</i> the level of Assistant Professor (or equivalent).</p>	<ul style="list-style-type: none"> • Fund basic and clinically oriented research relevant to NF and/or Schwannomatosis. • Preliminary data required. • Optional Qualified Collaborator: Collaborations that meet the criteria outlined in the Program Announcement/ Funding Opportunity will be qualified for a higher level of funding. • Clinical trials not allowed. 	<ul style="list-style-type: none"> • The maximum period of performance is 3 years. • The maximum allowable funding for the entire period of performance is \$525,000 in direct costs (\$675,000 in direct costs if requesting an Optional Qualified Collaborator). • Indirect costs may be proposed in accordance with your institution's negotiated rate agreement. 	<p>Pre-application (LOI): April 29, 2010 5:00 p.m. ET</p> <p>Application: May 20, 2010 11:59 p.m. ET</p>

*Letter of Intent

Fiscal Year 2010 (FY10) Neurofibromatosis Research Program (NFRP) Reference Table of Award Mechanisms and Submission Requirements

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Investigator-Initiated Focused Research Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: W81XWH-10-NFRP-IIIRA</p>	<p>Principal Investigator: Must be an independent investigator <i>at or above</i> the level of Assistant Professor (or equivalent).</p> <p>Optional Qualified Collaborator: Must be <i>at or above</i> the level of Assistant Professor (or equivalent).</p>	<ul style="list-style-type: none"> • Fund basic and clinically oriented research relevant to NF and/or Schwannomatosis. • Proposals must address one or more of the following research focus areas: Pain, wound repair, nerve regeneration, stress and inflammation, cognitive dysfunction and health-related quality of life, and/or neurofibromin protein. • Preliminary data required. • Optional Qualified Collaborator: Collaborations that meet the criteria outlined in the Program Announcement/ Funding Opportunity will be qualified for a higher level of funding. • Clinical trials not allowed. 	<ul style="list-style-type: none"> • The maximum period of performance is 3 years. • The maximum allowable funding for the entire period of performance is \$525,000 in direct costs (\$675,000 in direct costs if requesting an Optional Qualified Collaborator). • Indirect costs may be proposed in accordance with your institution's negotiated rate agreement. 	<p>Pre-application (LOI): April 29, 2010 5:00 p.m. ET</p> <p>Application: May 20, 2010 11:59 p.m. ET</p>

Fiscal Year 2010 (FY10) Neurofibromatosis Research Program (NFRP) Reference Table of Award Mechanisms and Submission Requirements

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Exploration – Hypothesis Development Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: W81XWH-10-NFRP-EHDA</p>	<p>All levels of experience.</p>	<ul style="list-style-type: none"> • Fund the initial exploration of innovative, untested research and pursue serendipitous observations. • <i>Preliminary data is encouraged but not required.</i> • Projects involving human subjects or human biological substances must be exempt under 32 CFR 219.101(b) or eligible for expedited review under 32 CFR 219.110 or 21 CFR 56.110. 	<ul style="list-style-type: none"> • The maximum period of performance is 2 years. • The maximum allowable funding for the entire period of performance is \$100,000 in direct costs. • Indirect costs may be proposed in accordance with your institution’s negotiated rate agreement. 	<p>Pre-application (LOI*): April 29, 2010 5:00 p.m. Eastern time (ET)</p> <p>Application: May 20, 2010 11:59 p.m. ET</p>
<p>New Investigator Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: W81XWH-10-NFRP-NIA</p>	<p>Must be an independent investigator <i>at or below</i> the level of Assistant Professor (or equivalent) with less than \$300,000 in direct costs in previous NF-related federal funding.</p>	<ul style="list-style-type: none"> • Fund investigators in the early stages of their careers. • Experience in NF research is allowed, but not required. • <i>Preliminary data required.</i> • Clinical trials not allowed. 	<ul style="list-style-type: none"> • The maximum period of performance is 3 years. • The maximum allowable funding for the entire period of performance is \$400,000 in direct costs. • Indirect costs may be proposed in accordance with your institution’s negotiated rate agreement. 	<p>Pre-application (LOI): April 29, 2010 5:00 p.m. ET</p> <p>Application: May 20, 2010 11:59 p.m. ET</p>

*Letter of Intent

Fiscal Year 2010 (FY10) Neurofibromatosis Research Program (NFRP) Reference Table of Award Mechanisms and Submission Requirements

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Postdoctoral Traineeship Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: W81XWH-10-NFRP-PTA</p>	<p>Postdoctoral Ph.D. PIs**:</p> <ul style="list-style-type: none"> • Must have successfully defended a doctoral thesis by September 1, 2010 ; <i>and</i> • Must not have been in the setting of the proposed research for more than 3 years; <i>and</i> • Must have 5 years or less of postdoctoral research experience. <p>Postdoctoral M.D. and D.O. PIs:</p> <ul style="list-style-type: none"> • Must have an M.D. or D.O. degree; <i>and</i> • Must be able to devote at least 40% effort; <i>and</i> • By August 1, 2010, must be: <ul style="list-style-type: none"> ▪ Enrolled in an accredited intern training program; <i>or</i> ▪ Enrolled in an accredited residency or fellowship training program with at least 2 years of training remaining; <i>or</i> ▪ Within 3 years of last formal training. 	<ul style="list-style-type: none"> • Enable recent medical or other doctoral degree graduates to obtain the necessary experience to pursue an independent career in NF research. • Funds can cover salary, travel, and tuition, but <u>not</u> research. 	<ul style="list-style-type: none"> • The maximum period of performance is 2 years. • The maximum allowable funding for the entire period of performance is \$100,000 in direct costs. • Indirect costs may be proposed in accordance with your institution's negotiated rate agreement. 	<p>Pre-application (LOI): April 29, 2010 5:00 p.m. ET</p> <p>Confidential Letters of Recommendation: May 20, 2010 5:00 p.m. ET</p> <p>Application: May 20, 2010 11:59 p.m. ET</p>

****Principal Investigators**